UB Paderborn / Katalog / Suche / in CDI

Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency

Blood, 2016-07, Vol.128 (1), p.45-54

2016

Volltextzugriff (PDF)

Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety

Molecular therapy, 2018-03, Vol.26 (3), p.917-931

2018

Volltextzugriff (PDF)

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Diabetologia, 2016-02, Vol.59 (2), p.266-274

2016

Volltextzugriff (PDF)

Inhaled Insulin Using the AERx Insulin Diabetes Management System in Healthy and Asthmatic Subjects

Diabetes care, 2003-03, Vol.26 (3), p.764-769

2003

Volltextzugriff (PDF)

Safety and biodistribution of XC001 (encoberminogene rezmadenovec) gene therapy in rats: a potential therapy for cardiovascular diseases

Gene therapy, 2024-01, Vol.31 (1-2), p.45-55

2024

Volltextzugriff (PDF)

Insulin-Like Growth Factor 1 Regulates Developing Brain Glucose Metabolism

Proceedings of the National Academy of Sciences - PNAS, 2000-08, Vol.97 (18), p.10236-10241

2000

Volltextzugriff (PDF)

Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations

The American heart journal, 2021-11, Vol.241, p.38-49

2021

Volltextzugriff (PDF)

Continuous subcutaneous Insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study

Diabetes care, 2003-09, Vol.26 (9), p.2598-2603

2003

Volltextzugriff (PDF)

Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide

Postgraduate medicine, 2014-05, Vol.126 (3), p.35-46

2014

Volltextzugriff (PDF)

Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist

Postgraduate medicine, 2014-11, Vol.126 (7), p.84-97

2014

Volltextzugriff (PDF)

Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes

Postgraduate medicine, 2016-05, Vol.128 (4), p.391-397

2016

Volltextzugriff (PDF)

Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program

Postgraduate medicine, 2017-11, Vol.129 (8), p.849-857

2017

Volltextzugriff (PDF)

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic Subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm

Diabetes care, 2004-06, Vol.27 (6), p.1324-1329

2004

Volltextzugriff (PDF)

Comparison of Insulin aspart with buffered regular Insulin and Insulin lispro in continuous subcutaneous Insulin infusion: A randomized study in type 1 diabetes

Diabetes care, 2002-03, Vol.25 (3), p.439-444

2002

Volltextzugriff (PDF)

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

Diabetes therapy, 2014-06, Vol.5 (1), p.141-153

2014

Volltextzugriff (PDF)

The Pro12Ala Variant of the PPARG Gene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-γ/α Agonist-Induced Edema in Type 2 Diabetic Patients

The journal of clinical endocrinology and metabolism, 2006-09, Vol.91 (9), p.3446-3450

2006

Volltextzugriff (PDF)

Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

Diabetes therapy, 2014-12, Vol.5 (2), p.609-609

2014

Volltextzugriff (PDF)

Young and Elderly Type 2 Diabetic Patients Inhaling Insulin with the AERx® Insulin Diabetes Management System: A Pharmacokinetic and Pharmacodynamic Comparison

Journal of clinical pharmacology, 2003-11, Vol.43 (11), p.1228-1234

2003

Volltextzugriff (PDF)

Biochemical and Morphometric Analyses Show that Myelination in the Insulin-like Growth Factor 1 Null Brain Is Proportionate to Its Neuronal Composition

The Journal of neuroscience, 1998-08, Vol.18 (15), p.5673-5681

1998

Volltextzugriff (PDF)

Effects of different durations of breath holding after inhalation of insulin using the AERx ® insulin diabetes management system

Clinical therapeutics, 2003-08, Vol.25 (8), p.2233-2244

2003

Volltextzugriff (PDF)

Ragaglitazar Improves Glycemic Control and Lipid Profile in Type 2 Diabetic Subjects

Diabetes care, 2004-06, Vol.27 (6), p.1324-1329

2004

Volltextzugriff (PDF)

Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes

Diabetes care, 2003-09, Vol.26 (9), p.2598-2603

2003

Volltextzugriff (PDF)

Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion

Diabetes care, 2002-03, Vol.25 (3), p.439-444

2002

Volltextzugriff (PDF)

Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases

The Journal of clinical investigation, 1995-04, Vol.95 (4), p.1528-1538

1995

Volltextzugriff (PDF)

The prol2ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in type 2 diabetic patients

The journal of clinical endocrinology and metabolism, 2006, Vol.91 (9), p.3446-3450

2006

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency

Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Inhaled Insulin Using the AERx Insulin Diabetes Management System in Healthy and Asthmatic Subjects

Safety and biodistribution of XC001 (encoberminogene rezmadenovec) gene therapy in rats: a potential therapy for cardiovascular diseases

Insulin-Like Growth Factor 1 Regulates Developing Brain Glucose Metabolism

Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations

Continuous subcutaneous Insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study

Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide

Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist

Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes

Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic Subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm

Comparison of Insulin aspart with buffered regular Insulin and Insulin lispro in continuous subcutaneous Insulin infusion: A randomized study in type 1 diabetes

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

The Pro12Ala Variant of the PPARG Gene Is a Risk Factor for Peroxisome Proliferator-Activated Receptor-γ/α Agonist-Induced Edema in Type 2 Diabetic Patients

Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

Young and Elderly Type 2 Diabetic Patients Inhaling Insulin with the AERx® Insulin Diabetes Management System: A Pharmacokinetic and Pharmacodynamic Comparison

Biochemical and Morphometric Analyses Show that Myelination in the Insulin-like Growth Factor 1 Null Brain Is Proportionate to Its Neuronal Composition

Effects of different durations of breath holding after inhalation of insulin using the AERx ® insulin diabetes management system

Ragaglitazar Improves Glycemic Control and Lipid Profile in Type 2 Diabetic Subjects

Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes

Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion

Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases

The prol2ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in type 2 diabetic patients

Suchergebnisse filtern